Investigating the role of tumor-infiltrating lymphocytes in advanced HER2-positive breast cancer

Chin Clin Oncol. 2018 Feb;7(1):2. doi: 10.21037/cco.2017.10.06. Epub 2017 Nov 14.

Authors

Stephen J Luen¹, Sherene Loi²

Affiliations

¹ Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australia.
² Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australia. sherene.loi@petermac.org.

PMID: 29156891
DOI: 10.21037/cco.2017.10.06

No abstract available

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Breast Neoplasms / drug therapy
Breast Neoplasms / enzymology*
Breast Neoplasms / immunology*
Breast Neoplasms / pathology
Docetaxel
Female
Humans
Lymphocytes, Tumor-Infiltrating / enzymology*
Lymphocytes, Tumor-Infiltrating / immunology*
Randomized Controlled Trials as Topic
Receptor, ErbB-2 / antagonists & inhibitors
Receptor, ErbB-2 / immunology*
Taxoids / administration & dosage
Trastuzumab / administration & dosage

Substances

Antibodies, Monoclonal, Humanized
Taxoids
Docetaxel
ERBB2 protein, human
Receptor, ErbB-2
pertuzumab
Trastuzumab